151 related articles for article (PubMed ID: 36285687)
1. Small molecule inhibitor against onco-mucins disrupts Src/FosL1 axis to enhance gemcitabine efficacy in pancreatic ductal adenocarcinoma.
Zhang C; Atri P; Nallasamy P; Parte S; Rauth S; Nimmakayala RK; Marimuthu S; Chirravuri-Venkata R; Bhatia R; Halder S; Shah A; Cox JL; Smith L; Kumar S; Foster JM; Kukreja RC; Seshacharyulu P; Ponnusamy MP; Batra SK
Cancer Lett; 2022 Dec; 551():215922. PubMed ID: 36285687
[TBL] [Abstract][Full Text] [Related]
2. MUC4 enhances gemcitabine resistance and malignant behaviour in pancreatic cancer cells expressing cancer-associated short O-glycans.
Sagar S; Leiphrakpam PD; Thomas D; McAndrews KL; Caffrey TC; Swanson BJ; Clausen H; Wandall HH; Hollingsworth MA; Radhakrishnan P
Cancer Lett; 2021 Apr; 503():91-102. PubMed ID: 33485947
[TBL] [Abstract][Full Text] [Related]
3. Low MUC4 expression is associated with survival benefit in patients with resectable pancreatic cancer receiving adjuvant gemcitabine.
Urey C; Andersson B; Ansari D; Sasor A; Said-Hilmersson K; Nilsson J; Andersson R
Scand J Gastroenterol; 2017 May; 52(5):595-600. PubMed ID: 28270046
[TBL] [Abstract][Full Text] [Related]
4. Aberrant expression of MUC3 and MUC4 membrane-associated mucins and sialyl Le(x) antigen in pancreatic intraepithelial neoplasia.
Park HU; Kim JW; Kim GE; Bae HI; Crawley SC; Yang SC; Gum JR; Batra SK; Rousseau K; Swallow DM; Sleisenger MH; Kim YS
Pancreas; 2003 Apr; 26(3):e48-54. PubMed ID: 12657964
[TBL] [Abstract][Full Text] [Related]
5. miR-219-1-3p is a negative regulator of the mucin MUC4 expression and is a tumor suppressor in pancreatic cancer.
Lahdaoui F; Delpu Y; Vincent A; Renaud F; Messager M; Duchêne B; Leteurtre E; Mariette C; Torrisani J; Jonckheere N; Van Seuningen I
Oncogene; 2015 Feb; 34(6):780-8. PubMed ID: 24608432
[TBL] [Abstract][Full Text] [Related]
6. Development and
Urey C; Hilmersson KS; Andersson B; Ansari D; Andersson R
Anticancer Res; 2017 Nov; 37(11):6031-6039. PubMed ID: 29061782
[TBL] [Abstract][Full Text] [Related]
7. Preclinical pharmacodynamic evaluation of a new Src/FOSL1 inhibitor, LY-1816, in pancreatic ductal adenocarcinoma.
Yang W; Meng L; Chen K; Tian C; Peng B; Zhong L; Zhang C; Yang X; Zou J; Yang S; Li L
Cancer Sci; 2019 Apr; 110(4):1408-1419. PubMed ID: 30618127
[TBL] [Abstract][Full Text] [Related]
8. Effects of thymoquinone in the expression of mucin 4 in pancreatic cancer cells: implications for the development of novel cancer therapies.
Torres MP; Ponnusamy MP; Chakraborty S; Smith LM; Das S; Arafat HA; Batra SK
Mol Cancer Ther; 2010 May; 9(5):1419-31. PubMed ID: 20423995
[TBL] [Abstract][Full Text] [Related]
9. Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance.
Andrianifahanana M; Moniaux N; Schmied BM; Ringel J; Friess H; Hollingsworth MA; Büchler MW; Aubert JP; Batra SK
Clin Cancer Res; 2001 Dec; 7(12):4033-40. PubMed ID: 11751498
[TBL] [Abstract][Full Text] [Related]
10. OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo.
Zhi X; Chen W; Xue F; Liang C; Chen BW; Zhou Y; Wen L; Hu L; Shen J; Bai X; Liang T
Oncotarget; 2015 Sep; 6(28):26230-41. PubMed ID: 26213847
[TBL] [Abstract][Full Text] [Related]
11. Yin Yang-1 suppresses invasion and metastasis of pancreatic ductal adenocarcinoma by downregulating MMP10 in a MUC4/ErbB2/p38/MEF2C-dependent mechanism.
Zhang JJ; Zhu Y; Xie KL; Peng YP; Tao JQ; Tang J; Li Z; Xu ZK; Dai CC; Qian ZY; Jiang KR; Wu JL; Gao WT; Du Q; Miao Y
Mol Cancer; 2014 May; 13():130. PubMed ID: 24884523
[TBL] [Abstract][Full Text] [Related]
12. The therapeutic targeting of the FGFR1/Src/NF-κB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and oncogenicity.
Lai SW; Bamodu OA; Tsai WC; Chang YM; Lee WH; Yeh CT; Chao TY
Clin Exp Metastasis; 2018 Oct; 35(7):663-677. PubMed ID: 29987671
[TBL] [Abstract][Full Text] [Related]
13. MUC4-promoted neural invasion is mediated by the axon guidance factor Netrin-1 in PDAC.
Wang L; Zhi X; Zhu Y; Zhang Q; Wang W; Li Z; Tang J; Wang J; Wei S; Li B; Zhou J; Jiang J; Yang L; Xu H; Xu Z
Oncotarget; 2015 Oct; 6(32):33805-22. PubMed ID: 26393880
[TBL] [Abstract][Full Text] [Related]
14. Mucin Expression and Splicing Determine Novel Subtypes and Patient Mortality in Pancreatic Ductal Adenocarcinoma.
Thompson CM; Cannon A; West S; Ghersi D; Atri P; Bhatia R; Smith L; Rachagani S; Wichman C; Kumar S; Batra SK
Clin Cancer Res; 2021 Dec; 27(24):6787-6799. PubMed ID: 34615717
[TBL] [Abstract][Full Text] [Related]
15. The antagonistic regulation of human MUC4 and ErbB-2 genes by the Ets protein PEA3 in pancreatic cancer cells: implications for the proliferation/differentiation balance in the cells.
Fauquette V; Perrais M; Cerulis S; Jonckheere N; Ducourouble MP; Aubert JP; Pigny P; Van Seuningen I
Biochem J; 2005 Feb; 386(Pt 1):35-45. PubMed ID: 15461591
[TBL] [Abstract][Full Text] [Related]
16. Combination of RUNX1 inhibitor and gemcitabine mitigates chemo-resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2α-axis-mediated endoplasmic reticulum stress.
She C; Wu C; Guo W; Xie Y; Li S; Liu W; Xu C; Li H; Cao P; Yang Y; Wang X; Chang A; Feng Y; Hao J
J Exp Clin Cancer Res; 2023 Sep; 42(1):238. PubMed ID: 37697370
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis of pancreatic neoplasms using a novel method of DNA methylation analysis of mucin expression in pancreatic juice.
Yokoyama S; Kitamoto S; Higashi M; Goto Y; Hara T; Ikebe D; Yamaguchi T; Arisaka Y; Niihara T; Nishimata H; Tanaka S; Takaori K; Batra SK; Yonezawa S
PLoS One; 2014; 9(4):e93760. PubMed ID: 24714692
[TBL] [Abstract][Full Text] [Related]
18. Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells.
Wissniowski TT; Meister S; Hahn EG; Kalden JR; Voll R; Ocker M
Int J Oncol; 2012 May; 40(5):1581-9. PubMed ID: 22266985
[TBL] [Abstract][Full Text] [Related]
19. Identification of inhibitors synergizing gemcitabine sensitivity in the squamous subtype of pancreatic ductal adenocarcinoma (PDAC).
Er JL; Goh PN; Lee CY; Tan YJ; Hii LW; Mai CW; Chung FF; Leong CO
Apoptosis; 2018 Jun; 23(5-6):343-355. PubMed ID: 29740790
[TBL] [Abstract][Full Text] [Related]
20. MUC4 mucin- a therapeutic target for pancreatic ductal adenocarcinoma.
Gautam SK; Kumar S; Cannon A; Hall B; Bhatia R; Nasser MW; Mahapatra S; Batra SK; Jain M
Expert Opin Ther Targets; 2017 Jul; 21(7):657-669. PubMed ID: 28460571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
